市场调查报告书

抗溃疡药的全球市场:2020年~2027年

Global Antiulcerant Drugs Market - 2020-2027

出版商 DataM Intelligence 商品编码 968990
出版日期 内容资讯 英文
商品交期: 最快1-2个工作天内
价格
抗溃疡药的全球市场:2020年~2027年 Global Antiulcerant Drugs Market - 2020-2027
出版日期: 2020年11月04日内容资讯: 英文
简介

全球抗溃疡药市场成长的主要因素有不健康的习惯的增加,开发中国家的人口的增加,繁忙的生活方式和糖尿病的高发。

本报告提供全球抗溃疡药市场相关调查分析,提供产业分析,各市场区隔的市场分析,竞争情形,主要企业等相关的系统性资讯。

目录

第1章 全球抗溃疡药市场:调查手法和范围

第2章 全球抗溃疡药市场:市场定义和概要

第3章 全球抗溃疡药市场:摘要整理

第4章 全球抗溃疡药市场:市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 机会
    • 影响分析

第5章 全球抗溃疡药市场:产业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 法规分析
  • 偿付分析
  • 未满足需求

第6章 全球抗溃疡药市场:COVID-19分析

  • COVID-19对市场的分析
  • COVID-19中的价格趋势
  • 供需频谱
  • 疫情期间与市场有关的政府举措
  • 制造商策略性举措
  • 结论

第7章 全球抗溃疡药市场:各类型

  • 简介
  • 市场规模分析·与前一年同期比较成长率分析:各类型
  • 市场魅力指数:种类各市场区隔
    • 氢离子帮浦阻断剂
    • H2受体拮抗剂
    • 抗生素
    • 胃粘膜保护药
    • 解酸剂
    • 前列腺素受体激动剂

第8章 全球抗溃疡药市场:各疾病

  • 简介
  • 市场规模分析·与前一年同期比较成长率分析:各疾病
  • 市场魅力指数:各疾病
    • 胃溃疡
    • 下肢溃疡
    • 消化性溃疡
    • 食道溃疡
    • 出血性溃疡
    • 难治性溃疡
    • 其他

第9章 全球抗溃疡药市场:各终端用户

  • 简介
  • 市场规模分析·与前一年同期比较成长率分析:各终端用户市场区隔
  • 市场魅力指数:各终端用户市场区隔
    • 医院
    • 诊所
    • 药局
    • 其他

第10章 全球抗溃疡药市场:各地区

  • 简介
  • 市场规模分析·与前一年同期比较成长率分析:各地区
  • 市场魅力指数:各地区
  • 北美
  • 欧洲
  • 南美
  • 亚太地区
  • 中东·非洲

第11章 全球抗溃疡药市场:竞争情形

  • 竞争模式
  • 市场定位/占有率分析
  • M&A分析

第12章 全球抗溃疡药市场:企业简介

  • Allergan Plc
  • AstraZeneca
  • Daewoong Pharmaceutical
  • Eisai
  • Takeda Pharmaceutical Company
  • Valeant
  • Zydus
  • Shire
  • Meritage Pharma
  • Medfit Biologicals等

第13章 全球抗溃疡药市场:重要考察

第14章 全球抗溃疡药市场:DataM

目录

Market Overview

The global antiulcerant drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Antiulcerant Drugs are a class of drugs or antibacterial agents that are used to treat ulcers especially in the stomach, upper part of the small intestine and other parts of body. The rising instance of heartburn and indigestion caused by the production of excess stomach acid has helped antiulcerant drugs occupy significant role in the treatment of stomach ulcers. Some antiulcerant drugs are also gaining popularity in the treatment of diarrhea or address an irritable gastrointestinal tract in patients.

Market Dynamics

The global antiulcerant drugs market market growth is driven by the as increasing unhealthy habits, rising population in the developing countries, swamped lifestyle and high prevalence of diabetes leading to foot ulcers.

Rising awareness about ulcer diseases is expected to drive the growth in the forecast period

There has been rising awareness about ulcer diseases, which has been imparting an increasing momentum to the evolution of the antiulcerant drugs market. The pipeline of promising antiulcerant drugs has been rising over the past few years in various parts of the world. In recent years, the pharmacology of antiulcerant drugs has received considerable attention by pharmaceutical companies, which has helped them develop drugs with better clinical results. The rising incidence of peptide ulcers, especially in people with sedentary lifestyle, is also catalyzing the growth of the global antiulcerant drugs market. The rising acceptance of antacids in anti-ulcer agents among the patient population for symptomatic relief is also a significant boosting the market..

Growing mortality of thrombotic events, especially in tuberculosis patients expected to drive the market growth

There is prevalence of infection with H. pylori in communities with the lack of access to clean water and proper sewage systems. This if untreated may lead to peptic ulcer disease, and antiulcerant drugs play crucial role in the treatment. The growing mortality of thrombotic events, especially in tuberculosis patients, is also likely to accentuate prospects of the antiulcerant drugs market in the coming few years. The rising risk of adverse cardiovascular events related to patients treated with aspirin has fueled the uptake of antiulcerant drugs. In recent years, several pharmaceuticals have been actively working to adopt advanced technologies for manufacturing anatacids. Moreover, they are spending sizeable sums on accelerating their drug pipelines. This will open new, exciting avenues in the global market.

Regulatory obstruction is likely to hinder the market growth

On the contrary, various side effects of the drug such as vomiting, nausea, menstrual disorders and stringent government regulations and policies related to drug patents may restrict the growth of the market.

COVID-19 Impact Analysis

The current utility-owned antiulcerant drugs market is affected mainly by the COVID-19 (Corona Virus Disease) pandemic. There has been delay in most ofthe projects that are in China, the US, Germany and South Korea, as well as companies in these regions are also facing temporaryoperative issues due to absence of site access and constrains in the supply chain. Due to the outburst of COVID-19 in china, Japan and India have shortage of these drugs. Thesse factors are restraning the growth of the market in the forecast period.

Segment Analysis

By type the antiulcerant drugs market is classified into proton pump inhibitors, H2 receptor antagonists, antibiotics, gastric mucosal protective drugs, antacids and prostaglandin agonists.

H2 receptor antagonist segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

H2 receptor antagonist, in full histamine receptor H2 antagonist, any agent that blocks histamine-induced secretion of gastric acid in the stomach. These drugs, which include cimetidine (Tagamet) and ranitidine (Zantac), are used for short-term treatment of gastroesophageal reflux and, in combination with antibiotics, for peptic ulcer.

According to International Foundation for Gastrointestinal Disorders, Inc., the prevalence of gastroesophageal reflux disease (GERD) was 18.1% to 27.8% in North America, 8.8% to 25.9% in Europe, 2.5% to 7.8% in East Asia, 8.7% to 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America in 2019. GERD is a chronic and highly prevalent disorder that can potentially lead to serious medical complications, and the medical expense involved in the diagnosis, treatment, and management of the disease is significant.

Rising awareness about gastroesophageal reflux disease and acid-peptic disease, availability of treatment options, and management of these diseases, have increased the demand for the treatment of H2-receptor antagonists in developing countries. Governments and other non-profit organizations spread awareness and educate people about gastric acid management through campaigns and educational and clinical workshops. These factors are driving the growth of the market in the forecast period.

The peptic ulcers are expected to dominate the antiulcerant drugs market during the forecast period

Sores that develop on the lining of stomach, esophagus, and intestines are called peptic ulcers. Symptoms of peptic ulcers include vomiting, burning stomach pain, bloating, and food intolerance. Some of the causes of peptic ulcers are stomach infections caused by H. pylori, alcoholism, stomach cancers, usage of anti-inflammatory drugs such as aspirin. Peptic ulcers, if untreated, can cause severe complications such as internal bleeding and perforation in the stomach lining. Lifestyle related factors such as aerated drinks, alcoholism, consumption of fatty food, and stress can cause peptic ulcers. Peptic ulcers can cause severe morbidity in the geriatric population. Hence, increase in this population is a key factor projected to drive the market during the forecast period. Furthermore, increase in patient pool and rise in consumption of drugs such as aspirin, ibuprofen, and other inflammatory drugs are the other factors which drives the market in the forecast period.

Geographical Analysis

North America region holds the largest market share in global antiulcerant drugs

North America region is dominating the global antiulcerant drugs accounted for the largest market share in 2019. Rise in awareness about peptic ulcer treatment, usage of antiulcerant drugs, and increase in prevalence of stomach cancer in the region are attributed to the growth of the market in North America. Furthermore, unhealthy lifestyles, high health care expenditure, and sophisticated health care infrastructure are the major factors fueling the growth of the market in the region. In addition, long R&D and approval cycles are required due to capital-intensive nature in North America, which act as a stumbling stone for the growth of the market in the region.

Asia Pacific will exhibit the positive growth during the forecast period. Increasing prevalence of stomach ulcers and a large geriatric population base in both India and China are supporting the growth of the regional market. This can also be attributed to increased adoption and favorable legislation in developed economies such as Japan and China.

Competitive Landscape

The Antiulcerant Drugs is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Allergan, Daewoong Pharmaceutical, Eisai, Takeda Pharmaceutical Company, Valeant, Zydus, Shire, Meritage Pharma, Medfit Biologicals., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiulcerant drugs globally.

Allergan Plc.

Overview: Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products.

Product Portfolio: The Company's portfolio comprised of pharmaceutical products of specialties for ophthalmologic care, neuromuscular, dermatological and urologic medical devices primarily facial aesthetics products, breast plastic products.

Why Purchase the Report?

  • Visualize the composition of the antiulcerant drugs market segmentation by type, disease, end-user, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in antiulcerant drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of antiulcerant drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global antiulcerant drugs market report would provide an access to an approx. 61 market data table, 61 figures and 300 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Antiulcerant Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Antiulcerant Drugs Market- Market Definition and Overview

3. Global Antiulcerant Drugs Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Disease
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Antiulcerant Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising awareness about ulcer diseases
      • 4.1.1.2. Growing mortality of thrombotic events
    • 4.1.2. Restraints:
      • 4.1.2.1. Regulatory obstruction is likely to hinder the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Antiulcerant Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Antiulcerant Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Antiulcerant Drugs Market - By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Proton pump inhibitors *
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. H2 receptor antagonists
    • 7.3.3. Antibiotics
    • 7.3.4. Gastric mucosal protective drugs
    • 7.3.5. Antacids
    • 7.3.6. Prostaglandin agonists

8. Global Antiulcerant Drugs Market - By Disease

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
  • 8.3. Market Attractiveness Index, By Disease
    • 8.3.1. Stomach Ulcers *
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2.
      • 8.3.1.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Leg Ulcers
    • 8.3.3. Peptic Ulcers
    • 8.3.4. Esophageal Ulcer
    • 8.3.5. Bleeding Ulcer
    • 8.3.6. Refractory Ulcer
    • 8.3.7. Others

9. Global Antiulcerant Drugs Market - By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Hospital *
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Pharmaceutical Stores
    • 9.3.4. Others

10. Global Antiulcerant Drugs Market- By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Antiulcerant Drugs Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Antiulcerant Drugs Market - Company Profiles

  • 12.1. Allergan Plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca,
  • 12.3. Daewoong Pharmaceutical
  • 12.4. Eisai
  • 12.5. Takeda Pharmaceutical Company
  • 12.6. Valeant
  • 12.7. Zydus
  • 12.8. Shire
  • 12.9. Meritage Pharma
  • 12.10. Medfit Biologicals

LIST NOT EXHAUSTIVE

13. Global Antiulcerant Drugs Market - Premium Insights

14. Global Antiulcerant Drugs Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us